Edit
Alzheon, Inc. | Preserving Future Memories
https://www.alzheon.com/Last activity: 19.06.2024
Active
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com
Location: United States, Massachusetts, Framingham
Employees: 11-50
Total raised: $207M
Founded date: 2013
Funding Rounds 4
| Date | Series | Amount | Investors |
| 14.06.2024 | Series E | $100M | - |
| 29.04.2022 | Series D | $50M | - |
| 21.08.2020 | Grant | $47M | - |
| 08.04.2015 | Series A | $10M | - |
Mentions in press and media 19
| Date | Title | Description |
| 19.06.2024 | Alzheon: $100 Million Closed To Advance Development Of Oral Tablet For Treating Alzheimer’s Disease | Alzheon, a clinical-stage biopharmaceutical company developing a portfolio of product candidates and diagnostic assays for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, announced that it has raised ... |
| 14.06.2024 | Alzheon Raises $100M in Series E Financing | Alzheon, a Farmingham, MA-based clinical-stage biopharmaceutical company, raised $100M in Series E funding. The round was led by Alerce Medical Technology Partners. The company, which previously raised $50M through a Series D financing roun... |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 14.04.2022 | Alzheimer’s Drug Developer Alzheon Secures $50 Million | Biotechnology company Alzheon Inc. has raised $50 million in new venture capital to complete clinical trials of a potential oral medication for Alzheimer’s disease. Framingham, Mass.-based Alzheon is testing the drug in late-stage, Phase 3 ... |
| 14.04.2022 | Alzheimer's biotech Alzheon nets $50M Series D; Evelo puts PhI atopic dermatitis program on hold | A Framingham, MA-based biotech has some new cash to play with. Alzheon announced Thursday morning it has completed a $50 million Series D round aimed to advance a Phase III study for its oral Alzheimer’s program, as well as to he... |
| 04.06.2021 | Alzheon Announces First Patient Dosed in APOLLOE4 Phase 3 Trial of Oral ALZ‑801 in Patients with Early Alzheimer's Disease | Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the dosing of the first patient in its... |
| 20.08.2020 | Alzheon returns, with a $47M NIH grant and one last shot at a pivotal PhIII Alzheimer’s success | Alzheon has spent four years searching for investors, public or private, willing to back a large study for their once-failed Alzheimer’s drug. On Thursday, they finally found a benefactor. Martin Tolar The NIH’s Institute for ... |
| 02.05.2018 | Term Sheet — Wednesday, May 2 | 5 Qs WITH A DEALMAKER In February, Reddit co-founder Alexis Ohanian said he would step down from his daily role at the company to return to investing. Paid Content You can't secure what you can't see From ExtraHop “I still use Reddit to dis... |
| 02.04.2018 | Term Sheet — Monday, April 3 | BIRD BOOM Good morning from San Francisco, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Bird is already hitting some regulatory challenges as it hopes to expand across 50 U.S. markets by the end ... |
| 19.03.2018 | Term Sheet — Monday, March 19 | ANTITRUST SHOWDOWN Good morning, Term Sheet readers. Paid Content How can you protect what you can't see? From ExtraHop Here’s why this matters: • The merger fight has broad implications for various industries, specifically media and tech. ... |
Show more